The Adverse Drug Reaction Monitoring In Hospitals

Abstract

CLC Number:

R994.11

ZHANG Jing ,WANG Peng-yuan ,PANG Yi-sheng ,HOU Yong-fang. The Adverse Drug Reaction Monitoring In Hospitals [J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 54-56.

[1] 侯永芳.生产企业开展药品不良反应监测工作必要性分析[J].中国执业药师,2009,1:17-18.
[2] 刘翠丽.药品不良反应监测：医院责任升级[N].健康报,2011-11-01005.
[3] 刘翠丽,田春华,冯红云.医疗机构如何做好药品不良反应监测工作[J].中国药物警戒,2012,4:224-226.
[4] 卫生部.药品不良反应报告和监测管理办法[S].卫生部令第81号,2011.
[5] 高小坤.对优化医疗机构药品不良反应监测与报告体系的探讨[J].药学进展,2006,11:512-515.
[6] 王乐民.对药品不良反应务必“可疑即报”[N].健康报,2009-07-10001.
[7] 刘新社,祁秋菊,董玲莉.正确认识药品不良事件与药品不良反应的关系提高监管工作的针对性[J].中国药事,2008,7:547-549.
[8] 朱含涌,韦龙静.药品不良事件的成因与责任研究[J].中国药事,2006,10:594-597.
[9] National Coordinating Council for Medication Error Reporting and Prevention. NCCMERP Taxonomy of Medication Errors[S].1998.
[10] 卫生部,国家中医药管理局.处方管理办法(试行)[S]. http://www.moh.gov.cn/publicfiles/business/htmlfiles/wsb/.
[11] 王儒强,张士勇,曹迪.加强医院药品不良反应监测工作,提高医疗质量的几点思考[J].安徽医药,2008,10:996-997.
[12] 北京大学第一医院医院.北京大学第一医院医院概况[R].2009-07-03.http://www.bddyyy.com.cn/yygk/yyjs/20090703/354.shtml.
[13] 曹立亚.我国的药品不良反应监测概况[C].2005 年中国药师周大会报告论文集,2005: 1551.
[14] 夏佳,张晓兰.浅谈药物自发不良反应报告率估计与低报的影响因素[J].药物流行病学杂志,2012,01:35-37+44.
[15] 张秀梅,李连新,付燕霞.医院医务人员药品不良反应认知度调查[J].中国药业,2012,18:3-4.
[16] 张音,刘刚.医疗损害纠纷处理机制存在问题及解决措施[J].中国卫生质量管理,2009,3:59-62.
[17] Lindquist M.Data Quality Management in Pharmacovigilance[J].Drug Saf. 2004,27(12):857-70.
[18] 陈锋,杨世民.我国药物不良反应监测体系建设现状与存在的问题[J].医药导报,2006,25( 5):486-488.

The Adverse Drug Reaction Monitoring In Hospitals

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian. Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
[2]	ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
[3]	SU Xinxin, ZHAO Xiaoxiao, XIE Yanming. Real-world analysis of combined administration of elemene emulsion injection in patients with liver cancer [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 929-934.
[4]	HUANG Yanli, XIE Yanming, WANG Lianxin, SUN Linxi, LIU Huan, ZHUANG Yunni. Clinical applications of Ciwujia injection in elderly patients in the real world [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 935-939.
[5]	ZHANG Hongwei, LI Yuanyuan, XIE Yanming, MA Xiaochang, WANG Lianxin, WEI Ruili, SUN Linxi, XU Hongyan, ZHUANG Yan. The drug combination of Danshen Ligustrazine injection in the real world [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 851-856.
[6]	LIU Chang, LIN Huijun, SHEN Hongxia, YAN Meixing. Analysis of Adverse drug reactions of intravenous medication in pediatric inpatients in a tertiary children's hospital [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 762-766.
[7]	SUN Chunquan, XIE Yanming, HOU Hengyue. Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.
[8]	BAI Hehe, NIE Xiaojing, XIA Li, MA Li, WANG Jinping, PENG Lirong. Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1136-1139.
[9]	SUN Chunquan, XIE Yanming, HOU Hengyue. Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 36-40.
[10]	WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le. Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System [J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
[11]	CHENG Fengjingming, XIE Yanming, WANG Lianxin, MIAO Yu. Effect of Mailuoshutong Pills on Renal Function Indexes in the Real World Based on Propensity Scores [J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 537-541.
[12]	DAI Biao, LIANG Jun, XIA Qingrong, XU Yayun, CAO Yin, WU Xiaoping. Analysis of Splitting of Oral Tablets by Inpatients in a Psychiatric Hospital [J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 373-376.
[13]	YUAN Xingdong, XU Yuming, ZHOU Juan, XU Jin, ZHONG Changming, LIU Zhijun, ZHANG Wei. Influence of Chinese Hospital Pharmacovigilance System on Quality of ADR Reports in 2 Hospitals [J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 138-140.
[14]	JIANG Yongxian, PU Xinyu, CHEN Wenwen, TAO Wanjun, CHEN Juan, LI Gen. Countermeasures Against Risk of Neonatal Off-label Drug Use [J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 164-169.
[15]	WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei. Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring [J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.